NHS to divert £45 billion from other services for new medicines under UK-US trade deal

A new analysis published in *The BMJ* warns that up to £45 billion in NHS funding could be redirected from other healthcare services by 2036 to cover the costs of new medicines under the UK-US Trade and Economic Partnership Agreement (TEPA), signed in December 2023. The study, conducted by researchers examining the financial implications of the trade deal, highlights concerns that current NHS budgets may not sustain this shift without additional investment. The findings underscore tensions between expanding access to pharmaceuticals and maintaining existing healthcare infrastructure, such as hospitals and community services.

The analysis estimates that the trade deal’s provisions—designed to facilitate faster approvals and wider availability of US-developed medicines—could lead to a significant rise in NHS spending on drugs. This projection assumes no new funding is allocated to offset the increased costs, which would necessitate reallocating resources from other areas of care. Researchers caution that the financial pressure could strain an already underfunded system, potentially compromising non-drug-related services. The report calls for transparency in how trade agreements impact public health budgets, emphasizing the need for policymakers to balance economic commitments with healthcare sustainability.

Without additional funding or cost-containment measures, the NHS risks diverting critical resources from essential services to meet the financial demands of the trade deal. The study authors stress that while access to innovative treatments is vital, the broader implications for healthcare delivery must be carefully managed. As the UK implements TEPA, stakeholders will need to monitor its fiscal effects and advocate for funding solutions to prevent unintended consequences for patient care.